RxDoctor Payments Data

Emily Tylski, DO

Pulmonary Disease · Kansas City, MONPI 1740608546

Payments from drug & device makers

$8,261in general payments, 2019–2025

Across 67 payments — averaging $123.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • AstraZeneca$299
  • Sanofi$247
  • Regeneron Healthcare Solutions, Inc.$101
  • Amgen$92
  • Grifols USA, LLC$87
  • plus $453 from 17 others

What the payments were for

  • Travel & lodging$96512%
  • Food & beverage$1,29616%
  • Education$6,00073%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,261 in reported general payments places this provider in the 65th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$102,281
Medicare patients
221
Services billed
1,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab44$165,800
Trelegy ElliptaFluticasone/Umeclidin/Vilanter96$92,311
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$24,167
Spiriva RespimatTiotropium Bromide19$17,314
Breo ElliptaFluticasone/Vilanterol29$17,162
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$11,895
Incruse ElliptaUmeclidinium Bromide24$9,985
SymbicortBudesonide/Formoterol Fumarate13$4,285
Albuterol Sulfate HfaAlbuterol Sulfate112$2,647
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,122
Montelukast Sodium64$698
Ventolin HfaAlbuterol Sulfate12$670
Azelastine Hcl16$633
Fluticasone Propionate16$362
Famotidine23$269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$17$119,458149 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$21$29,20940 claims
AstraZenecaBreztri Aerosphere, Symbicort$299$28,45250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →